Influence of Single Nucleotide Polymorphisms of Carboxypeptidase D (CPD) Gene on Body Weight and Fat Mass Reduction by Perindopril in Obese Subjects: A Phase II, Multicenter, Double-blind Study

Trial Profile

Influence of Single Nucleotide Polymorphisms of Carboxypeptidase D (CPD) Gene on Body Weight and Fat Mass Reduction by Perindopril in Obese Subjects: A Phase II, Multicenter, Double-blind Study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Perindopril (Primary)
  • Indications Obesity
  • Focus Biomarker; Therapeutic Use
  • Sponsors Gene PreDiT
  • Most Recent Events

    • 18 May 2017 New trial record
    • 11 May 2017 Planned patients number has been changed from 160 to 139.
    • 11 May 2017 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top